A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

The researchers tested their new itaconate-based prodrugs in mice and found that at least two of them were highly effective. The treatment was well-absorbed, reduced inflammation, and stimulated hair ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...

The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in ...

Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.